Products for Research Use Only
RegisterLogin

PL265

CAT: 0804-HY-115500Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-115500Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PL265 is an orally active dual enkephalinase inhibitor. PL265 is a prodrug of PL254, which can simultaneously and efficiently inhibit neutral endopeptidase (Neprilysin) and Aminopeptidase N. PL265 can effectively protect and significantly increase the local concentration of enkephalins (such as Met-Enkephalin and Leu-Enkephalin) released by cells at the pain or inflammation sites, thereby activating μ and δ opioid receptors to produce a potent analgesic effect. PL254 can also inhibit leukotriene A4 hydrolase (LTA4H), which may contribute to its additional anti-inflammatory effect by reducing the production of pro-inflammatory mediator leukotriene B4 (LTB4) . PL265 can be used in non-addictive chronic pain research[1].
CAS Number
1206514-50-2
UNSPSC
12352005
Target
Endogenous Metabolite; Leukotriene Receptor; Opioid Receptor
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
CC(C)C(OC(C)OC(N[C@@H](C)P(C[C@@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C(N[C@@H](C)C(O)=O)=O)(O)=O)=O)=O
Molecular Formula
C28H37N2O9P
Molecular Weight
576.58
References & Citations
[1]Bonnard E, et al. Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain. Pharmacol Res Perspect. 2015 Mar;3 (2) :e00116. |[2]Reaux-Le Goazigo A, et al. Dual enkephalinase inhibitor PL265: a novel topical treatment to alleviate corneal pain and inflammation. Pain. 2019 Feb 1;160 (2) :307-21.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GTR19277374PL265

Popular Products